Long-term effects of metformin and lifestyle modification on nonalcoholic Fatty liver disease obese adolescents
- PMID: 20798858
- PMCID: PMC2925435
- DOI: 10.1155/2010/831901
Long-term effects of metformin and lifestyle modification on nonalcoholic Fatty liver disease obese adolescents
Abstract
Objective. To assess the long-term effects of metformin in combination with lifestyle intervention and its association between insulin levels and the degree of steatosis at ultrasonography (US) in obese adolescents. Methods. Thirty-five postpubertal obese boys were randomized into two groups: one receiving metformin in combination with a multidisciplinary lifestyle intervention versus a placebo group, which also received the same intervention. The visceral, subcutaneous fat and degree of steatosis were measured by ultrasonography. Fasting blood samples were collected to analyze glucose, insulin, insulin resistance, and aminotransferases. Repeated ANOVA measures were used to compare changes over time and between groups, and Spearman's correlations were used to identify an association between insulin and the degree of steatosis at US. Results. There was a positive correlation between the degree of steatosis at US with insulin concentrations and HOMA-IR. Long-term therapy plus metformin significantly reduced body weight, body mass index, insulin, HOMA-IR, and visceral fat. Conclusions. Metformin was more effective than the placebo in improving clinical parameters associated with obesity and steatosis.
Figures
Similar articles
-
Ultrasonographic and biochemical evaluation of visceral obesity in obese women with non-alcoholic fatty liver disease.Eur J Med Res. 2007 Feb 26;12(2):68-73. Eur J Med Res. 2007. PMID: 17369120
-
Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study.Eur J Endocrinol. 2010 Oct;163(4):585-92. doi: 10.1530/EJE-10-0570. Epub 2010 Jul 16. Eur J Endocrinol. 2010. PMID: 20639355 Clinical Trial.
-
Long-term effects of aerobic plus resistance training on the adipokines and neuropeptides in nonalcoholic fatty liver disease obese adolescents.Eur J Gastroenterol Hepatol. 2012 Nov;24(11):1313-24. doi: 10.1097/MEG.0b013e32835793ac. Eur J Gastroenterol Hepatol. 2012. PMID: 22932160 Clinical Trial.
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
-
Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.Am J Gastroenterol. 2003 Sep;98(9):2093-7. doi: 10.1111/j.1572-0241.2003.07670.x. Am J Gastroenterol. 2003. PMID: 14499793 Review.
Cited by
-
Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3).Mol Pharm. 2015 Dec 7;12(12):4301-10. doi: 10.1021/acs.molpharmaceut.5b00501. Epub 2015 Nov 16. Mol Pharm. 2015. PMID: 26528626 Free PMC article.
-
Benefits of Physical Exercise as Approach to Prevention and Reversion of Non-Alcoholic Fatty Liver Disease in Children and Adolescents with Obesity.Children (Basel). 2022 Aug 5;9(8):1174. doi: 10.3390/children9081174. Children (Basel). 2022. PMID: 36010064 Free PMC article. Review.
-
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.Diabetologia. 2012 Apr;55(4):885-904. doi: 10.1007/s00125-011-2446-4. Epub 2012 Jan 27. Diabetologia. 2012. PMID: 22278337
-
Lipotoxicity: effects of dietary saturated and transfatty acids.Mediators Inflamm. 2013;2013:137579. doi: 10.1155/2013/137579. Epub 2013 Jan 31. Mediators Inflamm. 2013. PMID: 23509418 Free PMC article.
-
Metformin: an old but still the best treatment for type 2 diabetes.Diabetol Metab Syndr. 2013 Feb 15;5(1):6. doi: 10.1186/1758-5996-5-6. Diabetol Metab Syndr. 2013. PMID: 23415113 Free PMC article.
References
-
- Machado M, Cortez-Pinto H. Non-alcoholic fatty liver disease and insulin resistance. European Journal of Gastroenterology and Hepatology. 2005;17(8):823–826. - PubMed
-
- Tock L, Prado WL, Caranti DA, et al. Nonalcoholic fatty liver disease decrease in obese adolescents after multidisciplinary therapy. European Journal of Gastroenterology and Hepatology. 2006;18(12):1241–1245. - PubMed
-
- Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. American Journal of Gastroenterology. 2005;100(5):1082–1090. - PubMed
-
- Dâmaso AR, do Prado WL, de Piano A, et al. Relationship between nonalcoholic fatty liver disease prevalence and visceral fat in obese adolescents. Digestive and Liver Disease. 2008;40(2):132–139. - PubMed
-
- van der Poorten D, Milner K-L, Hui J, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008;48(2):449–457. - PubMed
LinkOut - more resources
Full Text Sources